Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3249-3259

  Varadan, Vinay ^a   Gilmore, Hannah ^b   Miskimen, Kristy L S ^a   Tuck, David ^c   Parsai, Shikha ^a   Awadallah, Amad ^b   Krop, Ian E ^d   Winer, Eric P ^d   Bossuyt, Veerle ^e   Somlo, George ^f   Abu Khalaf, Maysa M ^e   Fenton, Mary Anne ^g   Sikov, William ^g   Harris, Lyndsay N ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CURIS INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e YALE CANCER CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD4 ANTIGEN; DOCETAXEL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; B LYMPHOCYTE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER STAGING; CELL INFILTRATION; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MACROPHAGE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RNA SEQUENCE; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR BIOPSY; BIOSYNTHESIS; BREAST TUMOR; CLINICAL TRIAL; FEMALE; GENE EXPRESSION PROFILING; HELPER CELL; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ALBUMINS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B-LYMPHOCYTES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; MACROPHAGES; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, ERBB-2; T-LYMPHOCYTES, HELPER-INDUCER; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84977071121     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2021     Document Type: Article

References (34)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 2014;111:1888-98.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
5. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014;32:3744-52.
6. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13:1198-207.
7. Varadan V, Sandoval M, Harris LN. Biomarkers for predicting response to anti-HER2 agents. In: Stearns V, editor. Novel biomarkers in the continuum of breast cancer: New York: Springer; in press.
8. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014;15:e58-68.
9. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5.
10. Denkert C, Darb-Esfahani S, Loibl S, Anagnostopoulos I, Johrens K. Anticancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol 2011;33:341-51.
11. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014;25:1544-50.
12. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2015;33:701-8.
13. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007;6:2065-72.
14. Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 2009;58:1887-96.
15. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;123:2873-92.
16. Galanina N, Sprecher S, Bossuyt V, Sarkar S, Krop I, Winer E, et al. Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer. J Clin Oncol 2012;30:(suppl; abstr 10558).
17. Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, et al. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer 2015;15:24-30.
18. Residual cancer burden calculator; 2013.Available from: http://www.mdanderson.org/education-and-research/resources-for-professionals/clinicaltools-and-resources/clinical-calculators/index.html
19. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22.
20. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
21. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010;16:5222-32.
22. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013;4:2612.
23. Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 2014;20:3818-29.
24. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48-61.
25. Carey L, Barry WT, Pitcher B, Hoadley KA, Cheang MC, Anders CK, et al. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). J Clin Oncol 2014;32:suppl; abstr 506.
26. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2016;34:542-9.
27. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
28. Heinonen MT, Kanduri K, Lahdesmaki HJ, Lahesmaa R, Henttinen TA. Tubulin- and actin-associating GIMAP4 is required for IFN-gamma secretion during Th cell differentiation. Immunol Cell Biol 2015;93:158-66.
29. McDermott DS, Varga SM. Quantifying antigen-specific CD4 Tcells during a viral infection: CD4 T cell responses are larger than we think. J Immunol 2011;187:5568-76.
30. Mortenson ED, Park S, Jiang Z, Wang S, Fu YX. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res 2013;19:1476-86.
31. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
32. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011;29:2342-9.
33. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014;15:1137-46.
34. Durkee BY, Qian Y, Pollom EL, King MT, Dudley SA, Shaffer JL, et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015. Epub ahead of print.